
A Company Designing a Healthy Future
Neo Cremar pioneers innovation in the food industry with top-tier technology and state-of-the-art manufacturing facilities.
Neo Cremar Co., Ltd.
Healthcare Industry
Prebiotics

A Company Designing a Healthy Future
Neo Cremar pioneers innovation in the food industry with top-tier technology and state-of-the-art manufacturing facilities.
What is NeoCremar?
Neo Cremar is a company that prioritizes people and strives for health beyond just food.
Neo Cremar is a company that prioritizes people and strives for health beyond just food.
Domestic clients
A trusted business partner chosen by leading food companies in Korea
Domestic clients
A trusted business partner chosen by leading food companies in Korea
Overseas Clients
Leveraging outstanding technological expertise, expanding into the global market with a comprehensive network.
Overseas Clients
Leveraging outstanding technological expertise, expanding into the global market with a comprehensive network.
Import Sales
Discovery and exclusive supply of global premium ingredients selected under strict standards
Import Sales
Discovery and exclusive supply of global premium ingredients selected under strict standards
In-house Production
Proprietary production system based on unique patented technology and advanced facilities
In-house Production
Proprietary production system based on unique patented technology and advanced facilities
What is NeoCremar?
Neo Cremar is a company that prioritizes people and strives for health beyond just food.
Domestic clients
A trusted business partner chosen by leading food companies in Korea
Overseas Clients
Leveraging outstanding technological expertise, expanding into the global market with a comprehensive network.
Import Sales
Discovery and exclusive supply of global premium ingredients selected under strict standards
In-house Production
Proprietary production system based on unique patented technology and advanced facilities
Food Tech Business
Key Milestones
Food Tech Business
Key Milestones
01
KOSDAQ Listing
This company, recognized for its stability and growth potential, is listed on the KOSDAQ market.

01
KOSDAQ Listing
This company, recognized for its stability and growth potential, is listed on the KOSDAQ market.

02
Venture Company Certification
We have obtained venture company certification based on our technological capabilities and innovation.

02
Venture Company Certification
We have obtained venture company certification based on our technological capabilities and innovation.

03
Awarded the Five Million Dollar Export Tower
With global competitiveness, we have achieved exports exceeding 5 million USD annually.

03
Awarded the Five Million Dollar Export Tower
With global competitiveness, we have achieved exports exceeding 5 million USD annually.

ESG Strategy
Neo Cremar upholds ESG management as a core value and implements systematic strategies for sustainable growth.
ESG Strategy
Neo Cremar upholds ESG management as a core value and implements systematic strategies for sustainable growth.
Business
Through continuous research and quality innovation, we create a healthy food culture and provide enriching life values with reliable technological expertise.
Business
Through continuous research and quality innovation, we create a healthy food culture and provide enriching life values with reliable technological expertise.
Our Clients & Collaborators
Our News
Explore the latest corporate news from Neo Cremar.
Our News
Explore the latest corporate news from Neo Cremar.

CPHI Korea 2026 참가
CPHI Korea는 국내외 제약·바이오·헬스케어 산업의 공급망과 비즈니스를 연결하는 한국 대표 B2B 전시회입니다.
2026년 행사는 서울 COEX에서 8월 25~27일 개최되며, 의약품 원료사·바이오 기업·CDMO/OEM 기업·제약 설비업체·뉴트라슈티컬 및 건강기능식품 관련 기업과 국내외 바이어·의사결정자들이 참가합니다.
주요 특징:
80개 이상 국가·지역 참가
420개 이상 전시기업
12,000명 이상 방문객
의약품 원료, 바이오의약품, CDMO, 제약 설비, 뉴트라슈티컬·건강기능식품 등이 핵심 분야
부스위치
C15
Aug 25, 2026

CPHI Korea 2026 참가
CPHI Korea는 국내외 제약·바이오·헬스케어 산업의 공급망과 비즈니스를 연결하는 한국 대표 B2B 전시회입니다.
2026년 행사는 서울 COEX에서 8월 25~27일 개최되며, 의약품 원료사·바이오 기업·CDMO/OEM 기업·제약 설비업체·뉴트라슈티컬 및 건강기능식품 관련 기업과 국내외 바이어·의사결정자들이 참가합니다.
주요 특징:
80개 이상 국가·지역 참가
420개 이상 전시기업
12,000명 이상 방문객
의약품 원료, 바이오의약품, CDMO, 제약 설비, 뉴트라슈티컬·건강기능식품 등이 핵심 분야
부스위치
C15
Aug 25, 2026

CPHI Korea 2026 참가
CPHI Korea는 국내외 제약·바이오·헬스케어 산업의 공급망과 비즈니스를 연결하는 한국 대표 B2B 전시회입니다.
2026년 행사는 서울 COEX에서 8월 25~27일 개최되며, 의약품 원료사·바이오 기업·CDMO/OEM 기업·제약 설비업체·뉴트라슈티컬 및 건강기능식품 관련 기업과 국내외 바이어·의사결정자들이 참가합니다.
주요 특징:
80개 이상 국가·지역 참가
420개 이상 전시기업
12,000명 이상 방문객
의약품 원료, 바이오의약품, CDMO, 제약 설비, 뉴트라슈티컬·건강기능식품 등이 핵심 분야
부스위치
C15
Aug 25, 2026

Initiation of Preclinical Study for Functionality Evaluation of NeoGOS-P70 in Companion Animals
NeoCremar has initiated a preclinical study to validate the veterinary functional efficacy of its galacto-oligosaccharide ingredient, NeoGOS-P70.
This study, scheduled to run for approximately six months, will evaluate the potential of NeoGOS-P70 to improve gut health and skin barrier function in healthy companion dogs. The research will be conducted by Limpid Inc., a specialized veterinary clinical research organization, and will ensure scientific credibility through research advisory from the College of Veterinary Medicine at Seoul National University.
Through this study, NeoCremar aims to verify the potential application of NeoGOS-P70 in the companion animal sector and secure foundational data for future business expansion into the pet food and supplement markets. Furthermore, the company plans to pursue publication in international peer-reviewed journals based on the study findings.
We will continue to secure scientific evidence for our functional ingredients and expand the applicability of NeoGOS-P70 across diverse sectors.
Jun 5, 2026

Initiation of Preclinical Study for Functionality Evaluation of NeoGOS-P70 in Companion Animals
NeoCremar has initiated a preclinical study to validate the veterinary functional efficacy of its galacto-oligosaccharide ingredient, NeoGOS-P70.
This study, scheduled to run for approximately six months, will evaluate the potential of NeoGOS-P70 to improve gut health and skin barrier function in healthy companion dogs. The research will be conducted by Limpid Inc., a specialized veterinary clinical research organization, and will ensure scientific credibility through research advisory from the College of Veterinary Medicine at Seoul National University.
Through this study, NeoCremar aims to verify the potential application of NeoGOS-P70 in the companion animal sector and secure foundational data for future business expansion into the pet food and supplement markets. Furthermore, the company plans to pursue publication in international peer-reviewed journals based on the study findings.
We will continue to secure scientific evidence for our functional ingredients and expand the applicability of NeoGOS-P70 across diverse sectors.
Jun 5, 2026

Initiation of Preclinical Study for Functionality Evaluation of NeoGOS-P70 in Companion Animals
NeoCremar has initiated a preclinical study to validate the veterinary functional efficacy of its galacto-oligosaccharide ingredient, NeoGOS-P70.
This study, scheduled to run for approximately six months, will evaluate the potential of NeoGOS-P70 to improve gut health and skin barrier function in healthy companion dogs. The research will be conducted by Limpid Inc., a specialized veterinary clinical research organization, and will ensure scientific credibility through research advisory from the College of Veterinary Medicine at Seoul National University.
Through this study, NeoCremar aims to verify the potential application of NeoGOS-P70 in the companion animal sector and secure foundational data for future business expansion into the pet food and supplement markets. Furthermore, the company plans to pursue publication in international peer-reviewed journals based on the study findings.
We will continue to secure scientific evidence for our functional ingredients and expand the applicability of NeoGOS-P70 across diverse sectors.
Jun 5, 2026

Selected for the 2026 Regional Innovation Cluster R&D Initiative
NeoCremar has been selected as a joint research institution and has completed the agreement for the 'Development and Commercialization of Digestive Health Care Food Ingredients' project, a leading R&D initiative under the 'Regional Innovation Cluster Fosterage (R&D) Program' supported by the Ministry of Trade, Industry and Energy.
This project is led by Hamsoa Pharmaceutical Co., Ltd., with NeoCremar and the Korea Food Research Institute (KFRI) participating as joint research institutions, and will be conducted from 2026 to 2030. The project aims to develop functional ingredients to promote digestive health using AI technology, organoids, and multi-omics technologies, and to establish a foundation for the commercialization of health functional foods and care foods.
Through this project, NeoCremar plans to strengthen its research capabilities in functional ingredients, contribute to the development of next-generation functional ingredients in the digestive health sector, and commercialize individually approved health functional foods. Furthermore, based on industry-academia-research collaboration, we intend to enhance our competitiveness in domestic and global markets and secure new growth opportunities.
We will continue to do our best to strengthen our competitiveness in the functional ingredients sector and enhance corporate value through continuous research and development and technological innovation.
Jun 4, 2026

Selected for the 2026 Regional Innovation Cluster R&D Initiative
NeoCremar has been selected as a joint research institution and has completed the agreement for the 'Development and Commercialization of Digestive Health Care Food Ingredients' project, a leading R&D initiative under the 'Regional Innovation Cluster Fosterage (R&D) Program' supported by the Ministry of Trade, Industry and Energy.
This project is led by Hamsoa Pharmaceutical Co., Ltd., with NeoCremar and the Korea Food Research Institute (KFRI) participating as joint research institutions, and will be conducted from 2026 to 2030. The project aims to develop functional ingredients to promote digestive health using AI technology, organoids, and multi-omics technologies, and to establish a foundation for the commercialization of health functional foods and care foods.
Through this project, NeoCremar plans to strengthen its research capabilities in functional ingredients, contribute to the development of next-generation functional ingredients in the digestive health sector, and commercialize individually approved health functional foods. Furthermore, based on industry-academia-research collaboration, we intend to enhance our competitiveness in domestic and global markets and secure new growth opportunities.
We will continue to do our best to strengthen our competitiveness in the functional ingredients sector and enhance corporate value through continuous research and development and technological innovation.
Jun 4, 2026

Selected for the 2026 Regional Innovation Cluster R&D Initiative
NeoCremar has been selected as a joint research institution and has completed the agreement for the 'Development and Commercialization of Digestive Health Care Food Ingredients' project, a leading R&D initiative under the 'Regional Innovation Cluster Fosterage (R&D) Program' supported by the Ministry of Trade, Industry and Energy.
This project is led by Hamsoa Pharmaceutical Co., Ltd., with NeoCremar and the Korea Food Research Institute (KFRI) participating as joint research institutions, and will be conducted from 2026 to 2030. The project aims to develop functional ingredients to promote digestive health using AI technology, organoids, and multi-omics technologies, and to establish a foundation for the commercialization of health functional foods and care foods.
Through this project, NeoCremar plans to strengthen its research capabilities in functional ingredients, contribute to the development of next-generation functional ingredients in the digestive health sector, and commercialize individually approved health functional foods. Furthermore, based on industry-academia-research collaboration, we intend to enhance our competitiveness in domestic and global markets and secure new growth opportunities.
We will continue to do our best to strengthen our competitiveness in the functional ingredients sector and enhance corporate value through continuous research and development and technological innovation.
Jun 4, 2026







